What are the side effects of Tebentafusp-tebn?

The most common adverse reactions (≥30%) in patients receiving Tebentafusp-tebn for the treatment of uveal melanoma (UM) were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, cutaneous Dry skin, headache, and vomiting; the most common (≥50%) laboratory abnormalities in patients treated with tebenforx were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

Serious adverse reactions, including cytokine release syndrome, rash, fever, and hypotension, occurred in 28% of patients treated with tebenforx, and one patient (0.4%) experienced a fatal adverse reaction, pulmonary embolism. Adverse reactions leading to dose reduction occurred in 5% of patients treated with tebenforx, including cytokine release syndrome (2.4%) and rash (2%). Adverse reactions leading to dose interruption occurred in 25% of patients receiving tebenforx, including fatigue (3.7%), increased lipase (2.9%), pyrexia (2.4%), increased alanine aminotransferase (2%), and increased aspartate aminotransferase (2%). 3.3% of patients treated with tebenforx permanently discontinued treatment due to adverse reactions, including anaphylaxis, cerebral edema, cytokine release syndrome, fatigue, hepatotoxicity, hypotension, and nausea.

The original drug of Tibenforsi is not currently on the market in China, nor has it been included in medical insurance. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.